In announcement 06-10 of 15 March 2010, it was stated that NeuroSearch have issued new shares to the Board of Directors, the Executive Management and other employees following the exercise of warrants granted in 2005 under the company's warrant programme. Part of these recently issued shares has eventually been sold. Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch A/S (NEUR) shall make public transactions with shares and related securities of NeuroSearch A/S by persons discharging managerial responsibilities and persons/companies closely associated with these. Name: Flemming Pedersen Reason:CEO Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 10,765 Market value (DKK): 1,894,640 Name: Frank Wätjen Reason: Member of the Executive Management Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 6,745 Market value (DKK): 1,187,120 Name: Jørgen Drejer Reason: Member of the Executive Management Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 7,177 Market value (DKK): 1,263,152 Name: Allan Andersen Reason: Member of the Board of Directors Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 2,000 Market value (DKK): 354,193 Name: Torben Skov Reason: Member of the Board of Directors Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 2,007 Market value (DKK): 353,232 Name: Mads Gersdorff Korsgaard Reason: Member of the Board of Directors Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 861 Market value (DKK): 151,536 Name: Anita Milland Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 2,871 Market value (DKK): 505,296 Name: Dan Peters Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 3,587 Market value (DKK): 631,312 Name: Dorthe Filtenborg Olesen Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 1,291 Market value (DKK): 227,216 Name: Palle Christophersen Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 2,871 Market value (DKK): 505,296 Name: Thomas Varming Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 2,152 Market value (DKK): 378,752 Name: Daniel Brunicardi Timmermann Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 2,152 Market value (DKK): 378,752 Name: Naheed Mirza Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 4,162 Market value (DKK): 732,512 Name: Robin Sparks Reason: Member of the Management Group Issuer: NeuroSearch A/S ISIN code: DK0010224666 Transaction: Sale of shares Trade date: 18 March 2010 Market: NASDAQ OMX Copenhagen A/S Number (pcs): 1,435 Market value (DKK): 252,560 Contact person: Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations, tel: +45 4017 5103 About NeuroSearch - Company profile NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S. The core business of the company covers the development of novel pharmaceutical agents, based on a broad and well-established drug discovery platform, focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and GlaxoSmithKline, and licence collaboration with Abbott. The drug pipeline comprises eight clinical (Phase I-III) development programmes: Huntexil® (pridopidine) for Huntington's disease (Phase III), tesofensine for obesity (ready for Phase III), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR343 for schizophrenia (ready for Phase II), ACR325 to treat dyskinesias in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety/depression (Phase I) and NSD-721 for social anxiety disorder (Phase I) in partnership with GSK. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these
| Source: NTG Nordic Transport Group A/S